Navigation Links
Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
Date:3/17/2008

mitogen-activated ERK kinase (MEK) inhibitor, RDEA119, is in a Phase 1 study in advanced cancer patients and is being investigated for the treatment of inflammatory diseases. Ardea also is developing a next-generation NNRTI for HIV and a next-generation MEK inhibitor for both cancer and inflammatory diseases.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Ardea's goals, including the expected properties and benefits of RDEA806 and RDEA119 and its other compounds and the results of clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcomes of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, and costs associated with internal development and in-licensing activities. These and other risks and uncertainties are described more fully in Ardea's most recently filed SEC documents, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. Ardea undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


'/>"/>
SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
2. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
7. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
8. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
9. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
10. Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
11. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... , May 16, 2013  HeartWare International, Inc. (NASDAQ: ... of less invasive, miniaturized circulatory support technologies that are revolutionizing ... Doug Godshall is scheduled to present ... EDT on Monday, May 20, 2013.  The conference is being ... A live webcast of the Company,s presentation at ...
(Date:5/16/2013)... OAKS, Calif. , May 16, 2013  Amgen (NASDAQ: ... Life Sciences Conference on Tuesday, May 21, 2013, at the ... City , beginning at 10:00 a.m. Eastern Daylight Time. ... vice president of Research and Development at Amgen, will present ... accessed from the Events Calendar on Amgen,s website, www.amgen.com ...
(Date:5/16/2013)... , May 16, 2013 ... in the U.S. to access the widely-used OrthoView digital ... PC and Internet connection to get started. ... software for over 10 years, is dedicated to enabling ... with digital x-ray images, when printed film is unavailable. ...
Breaking Medicine Technology:HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast 2OrthoView Announces the U.S. Launch of a New, Subscription-based, Digital Planning and Templating Solution for Individual Orthopaedic Surgeons 2
... ERBITUX (cetuximab), the,first approved IgG1 monoclonal antibody ... and commercialized by,ImClone Systems Incorporated, was the ... at the recently concluded 43rd Annual Meeting,of ... This year's ASCO ERBITUX presentations showcased the ...
... attack,comparable to two widely used diabetes medicines , ... June 6, 2007 - A study,of more than 33,000 type ... study shows that the incidence of,hospitaliations for heart attack, and/or ... Avandia is the,same as for other diabetes treatments. The ...
Cached Medicine Technology:Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 2Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 3Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 4Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 5Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 6Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 7Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 8Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 9Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 10Newly Published Data from Large Study Support Cardiovascular Safety,of Avandia (Rosiglitazone Maleate) 2Newly Published Data from Large Study Support Cardiovascular Safety,of Avandia (Rosiglitazone Maleate) 3Newly Published Data from Large Study Support Cardiovascular Safety,of Avandia (Rosiglitazone Maleate) 4
(Date:5/18/2013)... SATURDAY, May 18 (HealthDay News) -- Children who swallow ... to remove the objects, according to a new study. ... Center in New Orleans, found that more than 79 ... required either surgery or an endoscopic procedure, in which ... digestive tract. Only 21 percent of these cases can ...
(Date:5/18/2013)... published an original art book for iPad with tango as ... who share their creations based on the traditional music genre ... iPad . , This work gathers more than 150 ... signature idiosyncrasy and passion of tango. Such book is ... it includes a free trailer of the book for readers ...
(Date:5/18/2013)... 2013) There are significant cost and risk ... diagnose or treat gastrointestinal problems, according to research ... A study by New York Presbyterian Hospital and ... may substantially reduce the cost and risk of ... believed to affect nearly 25 percent of adults, ...
(Date:5/18/2013)... In a May 14, 2013 article entitled ... Discovering Cancer Gene,” Fox News reported the movie star ... she carried a gene that doctors estimated gave her ... 50 percent risk of ovarian cancer (go to: goo.gl/5JHBP). ... 2013 with a blog post entitled “A Patient’s Journey: ...
(Date:5/18/2013)... A ground-breaking advance in colonoscopy technology signals ... presented today at Digestive Disease Week (DDW). Additional ... for colonoscopies and exploring safer methods for removing ... a device called a colonoscope to examine the ... a doctor to look for precancerous polyps called ...
Breaking Medicine News(10 mins):Health News:Swallowing Magnets Can Be Fatal for Children 2Health News:New Art Book for iPad: Tango Art 2Health News:New research identifies practice changes to improve value and quality of GI procedures 2Health News:Angelina Jolie – Scarless Breast Augmentation Surgery 2Health News:New colonoscope provides ground-breaking view of colon 2Health News:New colonoscope provides ground-breaking view of colon 3Health News:New colonoscope provides ground-breaking view of colon 4
... Stockholm, Sweden: Melanoma of the eye (ocular or uveal melanoma) ... there is no effective treatment and patients die within an ... ten patients live for a year. Now, final results from ... significantly extends the time patients can live without the disease ...
... People,s bodies build up vitamin D through exposure to sunlight, ... areas of the United States with low sunlight are more ... in the same places. The researchers say the findings ... study shows that across-the-board vitamin D recommendations just won,t work ...
... FRIDAY, Sept. 23 (HealthDay News) -- Foreign-born U.S. women are ... cancer, but native-born women still outpace them, a new study ... mammography among foreign-born women in the United States, but there ... their use of recommended breast cancer screening," study lead researcher ...
... disabilities increased in the U.S. among non-elderly adults during ... Mojtabai, MD, PhD, of the Johns Hopkins Bloomberg School ... found the prevalence of disability attributed to other chronic ... remained unchanged. The findings will appear in the November ...
... A little motivation for parents could go a long ... their own care, a Wayne State University researcher believes. ... in WSU,s School of Medicine, has received a two-year, ... Digestive and Kidney Diseases of the National Institutes of ...
... News) -- Many people who undergo MRI scans describe feeling ... and a new study may explain why. Researchers ... on fluid circulating in the inner ear, impacting balance and ... , In the study, published online Sept. 22 in ...
Cached Medicine News:Health News:Infusing chemotherapy into the liver gives extra months of disease-free life in melanoma patients 2Health News:Infusing chemotherapy into the liver gives extra months of disease-free life in melanoma patients 3Health News:Infusing chemotherapy into the liver gives extra months of disease-free life in melanoma patients 4Health News:Many Black Men in Cold Climates Lack Vitamin D 2Health News:Wayne State University study aims to improve diabetes management in high-risk youth 2Health News:Wayne State University study aims to improve diabetes management in high-risk youth 3Health News:Magnetic Field May Cause MRI-Induced Vertigo 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: